<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ICU</journal-id>
<journal-id journal-id-type="hwp">spicu</journal-id>
<journal-title>ICU Director</journal-title>
<issn pub-type="ppub">1944-4516</issn>
<issn pub-type="epub">1944-4524</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1944451612443067</article-id>
<article-id pub-id-type="publisher-id">10.1177_1944451612443067</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Bench to Bedside Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Parathyroid Hormone–Related Protein in the Healthy and Injured Lung</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Montgrain</surname><given-names>Philippe R.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1944451612443067">1</xref>
<xref ref-type="aff" rid="aff2-1944451612443067">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Hastings</surname><given-names>Randolph H.</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff3-1944451612443067">3</xref>
<xref ref-type="aff" rid="aff4-1944451612443067">4</xref>
</contrib>
</contrib-group>
<aff id="aff1-1944451612443067"><label>1</label>Medicine Service, VA San Diego Healthcare System; San Diego, California</aff>
<aff id="aff2-1944451612443067"><label>2</label>Department of Medicine, University of California, San Diego, La Jolla, California</aff>
<aff id="aff3-1944451612443067"><label>3</label>Anesthesiology Service, VA San Diego Healthcare System, San Diego, California</aff>
<aff id="aff4-1944451612443067"><label>4</label>Department of Anesthesiology, University of California, San Diego, La Jolla, California</aff>
<author-notes>
<corresp id="corresp1-1944451612443067">Randolph H. Hastings, MD, PhD, Anesthesiology Service, VA San Diego Healthcare System, 3350 La Jolla Village Drive (125), San Diego, CA 92161; e-mail: <email>rhhastings@ucsd.edu</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2012</year>
</pub-date>
<volume>3</volume>
<issue>3</issue>
<fpage>130</fpage>
<lpage>134</lpage>
<permissions>
<copyright-statement>© 2012 The Author(s)</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Parathyroid hormone–related protein (PTHrP) is an oncofetal protein with functional effects in normal and diseased lung. In the respiratory system, the hormone has implications for a variety of processes, including lung development, alveolar type II cell function and differentiation, cell proliferation, apoptosis, motility, and matrix interactions. PTHrP regulates branching morphogenesis and type II cell maturation in fetal lung through bidirectional interactions with lung fibroblasts. Consequently, it appears to have a role in the pathophysiology of respiratory distress syndrome and bronchopulmonary dysplasia. In adult lung, the molecule has autocrine actions on type II pneumocytes that stimulate phosphatidylcholine production, inhibit cell proliferation, and sensitize to apoptotic stimuli. Type II cell PTHrP levels fall after lung injury, inversely coordinated in time with their proliferation, suggesting that reduction in its growth inhibitory effect may contribute to the increase in type II cell numbers after injury. Air space levels of the protein are inversely related to the risk of lung injury or injury severity in neonatal and adult lung, consistent with its production by pneumocytes. Thus, PTHrP has clinical significance as a biomarker for injury and as a potential target for treatment.</p>
</abstract>
<kwd-group>
<kwd>parathyroid hormone–related protein</kwd>
<kwd>type II pneumocyte</kwd>
<kwd>lung development</kwd>
<kwd>lung injury</kwd>
<kwd>biomarker</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1944451612443067">
<title>Parathyroid Hormone–Related Protien Structure, Localization, and Function</title>
<p>Parathyroid hormone–related protein (PTHrP) is a well-known paraneoplastic protein that causes hypercalcemia of malignancy. It is also expressed in a host of normal tissues and plays a role in development and normal physiology. The protein was named because of similarities with parathyroid hormone. The amino termini of the 2 hormones, roughly the first 34 residues of each, share primary and secondary homology and bind to the same G protein coupled receptor, PTH1R. Hypercalcemia of malignancy results from activation of PTH1R in kidney and bone in the face of excess tumor production of PTHrP. In the absence of malignancy, however, PTHrP is generally undetectable in the circulation and its normal tissue effects, typically on growth cycle, calcium transport, smooth muscle and matrix adhesion,<sup><xref ref-type="bibr" rid="bibr1-1944451612443067">1</xref></sup> are exerted at a local, paracrine level.</p>
<p><disp-quote>
<p>“The predominant manifestations of PTHrP in lung stem from effects on development, alveolar epithelial cell growth, and surfactant synthesis.”</p>
</disp-quote></p>
<p>PTHrP has a complex structural organization. Through alternative gene splicing, it is expressed as isoforms that are 141, 139, and 173 amino acids in length. For most purposes, the 3 isoforms are difficult to distinguish on the basis of biology and functional consequences, not surprising given the identity in the first 139 residues. Furthermore, the isoforms are precursors to a family of smaller peptides that are actually responsible for the biologic activity.<sup><xref ref-type="bibr" rid="bibr2-1944451612443067">2</xref></sup> The PTHrP sequence contains a high number of single basic and multiple basic sites that can be recognized and attacked by proteolytic enzymes.<sup><xref ref-type="bibr" rid="bibr3-1944451612443067">3</xref></sup> The molecule undergoes considerable posttranslational processing and is secreted as a constellation of smaller daughter peptides, as well as forms close in size to the full-length protein.</p>
<p>Many of the daughter peptides have biologic effects, so PTHrP could be thought of as a multifunctional prohormone, similar to parathyroid hormone (PTH), chromogranin, and other endocrine hormones. In addition to the PTH-like amino domain, PTHrP has biologic activity localized to mid-molecule and carboxyl-terminal regions. Peptides contained within the PTHrP 38-94 region have effects on growth and calcium mobilization in various types of cancer cells,<sup><xref ref-type="bibr" rid="bibr2-1944451612443067">2</xref>,<xref ref-type="bibr" rid="bibr4-1944451612443067">4</xref></sup> whereas carboxyl PTHrP has negative effects on the bone-resorbing properties of osteoclasts,<sup><xref ref-type="bibr" rid="bibr5-1944451612443067">5</xref></sup> in effect opposing the stimulating action of amino PTHrP on osteoclasts. Even the most distal peptide region, PTHrP 140-173, has unique activity, specifically altering pyrophosphate metabolism in chondrocytes.<sup><xref ref-type="bibr" rid="bibr6-1944451612443067">6</xref></sup> The actions of the nonamino peptides are thought to be receptor-mediated but receptors are yet to be found. PTHrP also includes a nuclear localizing sequence (residues 87-106)<sup><xref ref-type="bibr" rid="bibr7-1944451612443067">7</xref></sup> and a distal nuclear export sequence<sup><xref ref-type="bibr" rid="bibr8-1944451612443067">8</xref></sup> that allow it to shuttle in and out of the nucleus. In the nucleus, PTHrP exerts intracrine effects on growth, motility, matrix adhesion, and related functions. Interestingly, the intracrine effects can oppose the paracrine, receptor-mediated effects of the molecule in some cases.<sup><xref ref-type="bibr" rid="bibr9-1944451612443067">9</xref></sup></p>
</sec>
<sec id="section2-1944451612443067">
<title>Parathyroid Hormone–Related Protein in Normal Lung</title>
<p>The predominant manifestations of PTHrP in lung stem from effects on development, alveolar epithelial cell growth, and surfactant synthesis. Because the protein relaxes smooth muscle, it could also have effects on bronchial and vascular tone, airway reactivity, and vascular resistance.<sup><xref ref-type="bibr" rid="bibr10-1944451612443067">10</xref>,<xref ref-type="bibr" rid="bibr11-1944451612443067">11</xref></sup> The protein also regulates various aspects of lung cancer phenotype, but this review will focus on factors that are more commonly and directly relevant to the critical care setting.</p>
<p>In terms of development, PTHrP affects both structural and functional aspects of lung maturation. Neonatal mice with PTHrP knockout die shortly after birth from respiratory failure.<sup><xref ref-type="bibr" rid="bibr12-1944451612443067">12</xref></sup> Targeted disruption of PTH1R leads to a similar clinical picture and lethal outcome,<sup><xref ref-type="bibr" rid="bibr13-1944451612443067">13</xref></sup> suggesting that loss of PTHrP 1-34 is important for the pathologic state. Skeletal abnormalities, which occur because PTHrP is involved in bone development, lead to problems with ventilation. Furthermore, the knockout mice display hypoplastic lungs with arrested alveolar formation, abnormal diphosphatidylcholine synthesis and deficiencies in surfactant apoproteins.<sup><xref ref-type="bibr" rid="bibr14-1944451612443067">14</xref></sup> Thus, PTHrP is involved in maturation of alveolar type II cell function and the developmental program surrounding branching morphogenesis.</p>
<p>The molecular mechanisms by which PTHrP contributes to lung development involve interesting interactions between fetal lung epithelial cells and fibroblasts. PTHrP and its receptor, PTH1R, are expressed in a hand and glove arrangement between the epithelial cells and fibroblasts,<sup><xref ref-type="bibr" rid="bibr15-1944451612443067">15</xref></sup> respectively, a spatial orientation that is also found in other tissues where PTHrP regulates development. PTHrP 1-34 derived from the fetal pneumocytes maintains fetal lung fibroblasts as lipofibroblasts and stimulates them to produce surfactant lipid precursors.<sup><xref ref-type="bibr" rid="bibr16-1944451612443067">16</xref></sup> Furthermore, PTHrP induces the lipofibroblasts to produce and secrete leptin, a signaling molecule that stimulates phosphatidylcholine production by the type II cells.<sup><xref ref-type="bibr" rid="bibr16-1944451612443067">16</xref></sup> In the absence of PTHrP, lipofibroblasts in developing lung differentiate into myofibroblasts, a cell type that does not support maturation of surfactant production and instead engenders a fibrotic phenotype. The actions of PTHrP in lipofibroblasts are mediated through PTH1R and involve cAMP-dependent increases in PPARγ (peroxisome proliferator–activated receptor-γ) as a downstream signaling molecule.<sup><xref ref-type="bibr" rid="bibr17-1944451612443067">17</xref></sup></p>
<p>Nicotine opposes PTHrP in some aspects and the dichotomy may tie into the deleterious reaction of developing lung to maternal smoking. In particular, nicotine decreases PPARγ levels in fetal lung fibroblasts and stimulates their transformation into myofibroblasts.<sup><xref ref-type="bibr" rid="bibr17-1944451612443067">17</xref></sup> Interestingly, PTHrP and dibutyryl cAMP will block these changes and supplementation with PPARγ will prevent transdifferentiation to myofibroblasts.<sup><xref ref-type="bibr" rid="bibr18-1944451612443067">18</xref></sup> The results imply that exposure to nicotine reduces fetal lung size and decreases surfactant synthetic capability because of a shift in fibroblast phenotype and that PTHrP opposes those effects.<sup><xref ref-type="bibr" rid="bibr19-1944451612443067">19</xref></sup> Thus, PTHrP agonists might be possible treatments to mitigate against the effects of maternal smoking in the developing fetal lung.</p>
<p>The effects of PTHrP in adult lung differ from those in fetal lung with respect to the relative distribution of PTHrP compared with its receptor. PTHrP and PTH1R are both expressed by type II cells in adult lung, rather than being separated between pneumocytes and fibroblasts. Still, some of the protein’s pulmonary effects are common between very young and mature ages. In fact, PTHrP 1-34 mediates increases in surfactant production in adult type II cells as in the fetal cells. The protein also stimulates expression of alkaline phosphatase and augments the number of lamellar bodies per type II cell, additional type II cell specific markers.<sup><xref ref-type="bibr" rid="bibr20-1944451612443067">20</xref></sup> Besides the effects on phenotype, PTHrP also has autocrine effects on pneumocyte life cycle. For example, treatment with neutralizing antibodies to PTHrP augments proliferation of cultured type II cells, an effect that is blocked by concurrent exposure to exogenous PTHrP 1-34.<sup><xref ref-type="bibr" rid="bibr21-1944451612443067">21</xref></sup> Finally, treatment with PTHrP 1-34 sensitizes type II cells to apoptosis induced by ultraviolet-B light.<sup><xref ref-type="bibr" rid="bibr22-1944451612443067">22</xref></sup> Given that adult type II cells are regulated by the PTHrP that they themselves produce, the signaling pathway is autocrine, as opposed to the bidirectional paracrine partnership with fibroblasts seen in fetal lung.</p>
<p>In addition to these effects in the adult lung, PTHrP could have a role in regulating pulmonary vascular pressures given its effects as a smooth muscle relaxant. The hormone has been well studied for its effects in relaxing the systemic circulation and blocking hypertension,<sup><xref ref-type="bibr" rid="bibr23-1944451612443067">23</xref></sup> but little work has been done on the pulmonary circulation. In one study, cultured bovine pulmonary artery endothelial cells treated with PTHrP had decreased production of endothelin-1.<sup><xref ref-type="bibr" rid="bibr24-1944451612443067">24</xref></sup> Thus, PTHrP deficiency might contribute to pulmonary hypertension in some settings and conceivably could be a target molecule for developing pulmonary vasodilators.</p>
</sec>
<sec id="section3-1944451612443067">
<title>Parathyroid Hormone–Related Protein in Lung Injury</title>
<p>Type II pneumocytes play a major role in the repair process after lung injury. They are more likely to survive injury than type I cells, they secrete surfactant and express ion pumps that help clear fluid from the alveolar space. In addition, type II cells are pluripotent. They contribute to repairing the alveolar barrier by proliferating, spreading, and differentiating into new type I cells. By virtue of its effects on type II cell proliferation, apoptosis and surfactant production and secretion, PTHrP could play a key role in regulating the repair process after lung injury. Evidence for a function of PTHrP in lung injury is provided by time course measurements. PTHrP levels generally fall shortly after the onset of injury and recover within 1 to 2 weeks, occasionally to supranormal levels. For example, in a rat hyperoxia model of lung injury, PTHrP levels reach a nadir of 15% of levels in normal control lungs at 4 to 8 days after onset of injury.<sup><xref ref-type="bibr" rid="bibr25-1944451612443067">25</xref></sup> Levels then recover by 10 days. Similarly, in a rat silica lung injury model, PTHrP levels are decreased at 4 days after instilling silica, then increase at 14 days.<sup><xref ref-type="bibr" rid="bibr26-1944451612443067">26</xref></sup> In both the hyperoxia and silica injury models, the fall in PTHrP levels coincides with the period of maximum type II cell proliferation. PTHrP levels then rise as pneumocyte proliferation diminishes over time. If the fall in PTHrP levels following lung injury is prevented by treatment with exogenous PTHrP the type II cell mitogenic response is decreased by 85% compared with controls.<sup><xref ref-type="bibr" rid="bibr25-1944451612443067">25</xref></sup> This suggests that PTHrP regulates type II cell proliferation in response to injury.</p>
<p>PTHrP may also serve as a useful biomarker. Levels of PTHrP in bronchoalveolar lavage (BAL) fluid negatively correlate with the severity of lung injury determined by lung injury score, severity of infiltrates on chest radiographs, and BAL albumin concentration in patients with acute lung injury.<sup><xref ref-type="bibr" rid="bibr27-1944451612443067">27</xref></sup> In addition, PTHrP levels are significantly lower in patients with PaO2/FiO2 ratios less than 150 mm Hg compared with ratios of 150 to 300 mm Hg. Thus, patients with the lowest PTHrP levels have the worst signs of injury and would be expected to have a worse prognosis. PTHrP may even serve to predict who will develop lung injury. In a study of patients undergoing pulmonary thromboendarterectomy (PTE) for chronic thromboembolic pulmonary hypertension, 23 patients developed lung injury after surgery. These patients had significantly lower preoperative BAL levels of PTHrP compared with the 25 patients without lung injury.<sup><xref ref-type="bibr" rid="bibr28-1944451612443067">28</xref></sup> A preoperative PTHrP level below 32 pg/mL was associated with a 6-fold increase in the odds of developing lung injury compared with patients with higher preoperative PTHrP levels.</p>
<p>PTHrP levels also correlate with several indexes of lung maturation in neonates. PTHrP levels in tracheal aspirates of newborn infants are significantly lower in infants born at less than 35 weeks’ gestation, with birth weights less than 2 kg, and in preterm infants with respiratory distress syndrome.<sup><xref ref-type="bibr" rid="bibr29-1944451612443067">29</xref></sup> Moreover, preterm infants exposed to steroids before delivery have higher levels of tracheal aspirate PTHrP. Finally, tracheal aspirate PTHrP levels during the first week of life of ventilated, low birth weight infants are inversely correlated with the risk of developing bronchopulmonary dysplasia.<sup><xref ref-type="bibr" rid="bibr30-1944451612443067">30</xref></sup> PTHrP deficiency may have an active role in the lung injury process leading to bronchopulmonary dysplasia,<sup><xref ref-type="bibr" rid="bibr31-1944451612443067">31</xref></sup> since the molecule is closely linked with the pathways regulating alveolar development as discussed above. The biomarker studies suggest that PTHrP may be an indicator of type II cell number and/or function in adult and neonatal lung and support a role for PTHrP in the lung injury repair process.</p>
</sec>
<sec id="section4-1944451612443067">
<title>Parathyroid Hormone–Related Protein in Inflammation</title>
<p>When PTHrP was discovered in malignant tissue, investigators noticed that it was expressed in cells that also expressed TNF-α, IL-1β, and IL-6.<sup><xref ref-type="bibr" rid="bibr32-1944451612443067">32</xref></sup> The close association with these mediators suggested that PTHrP might participate in the cytokine networks that drive inflammatory processes. Indeed, PTHrP is co-expressed with various cytokines during inflammation in a number of settings, including rheumatoid arthritis, ischemia-reperfusion injury, atherosclerosis, and sepsis.<sup><xref ref-type="bibr" rid="bibr33-1944451612443067">33</xref></sup> Sepsis is accompanied by increases in circulating PTHrP levels and increased production in spleen, liver, kidney, and lung. The hormone appears to be stimulated by TNF-α or IL-1β based on the time course for rise in expression, studies with knockout mice, and the effects of direct treatment with TNF-α or IL-1β blockers.</p>
<p>PTHrP’s role in inflammation is not well characterized but may be either beneficial or deleterious depending on the setting and context (<xref ref-type="fig" rid="fig1-1944451612443067">Figure 1</xref>).<sup><xref ref-type="bibr" rid="bibr32-1944451612443067">32</xref>,<xref ref-type="bibr" rid="bibr33-1944451612443067">33</xref></sup> In bone metastases and rheumatoid joints, the protein contributes to bone loss by stimulating IL-6 and/or RANK-ligand. PTHrP expression or treatment appears to improve outcome after ischemic injury in brain and heart, possibly through its vasodilatory properties to increase blood flow. PTHrP may have a beneficial role with mild levels of sepsis. The protein is expressed by the periportal hepatocytes that also make acute phase reactants and with a similar time course. In that role, PTHrP stimulates hepatic lipogenesis and expression of serum amyloid A, components of the response that is thought to neutralize inflammatory stimulants. In severe sepsis, however, PTHrP appears to contribute to lethality. Mice treated with high doses of endotoxin demonstrate improved survival curves if treated with neutralizing antibodies to PTHrP shortly after the initiation of the sepsis event. The negative effect may result in part from PTHrP-mediated vasodilation, accentuating hypotension during septic shock. PTHrP is ubiquitous in inflammatory processes that affect critical care medicine and PTHrP-based treatments might provide novel avenues for treatment. Further work is necessary, since the therapeutic goal might be to stimulate or block PTHrP depending on the setting.</p>
<fig id="fig1-1944451612443067" position="float">
<label>Figure 1.</label>
<caption>
<p>Role of parathyroid hormone–related protein (PTHrP) in the inflammatory cascade. PTHrP expression is typically stimulated by either TNF-α or IL-1β, 2 mediators that are activated by various inflammatory stimuli. PTHrP in turn can be involved in IL-6-mediated actions as shown, including the acute phase reaction, and it can cause vasodilation and bronchodilation through its actions as a smooth muscle relaxant.</p>
</caption>
<graphic xlink:href="10.1177_1944451612443067-fig1.tif"/>
</fig>
</sec>
<sec id="section5-1944451612443067" sec-type="conclusions">
<title>Conclusion</title>
<p>Parathyroid hormone–related protein is a complex, multifunctional protein that undergoes alternative gene splicing and extensive posttranslational processing, resulting in a number of bioactive peptides that can act via paracrine and intracrine mechanisms. Though initially discovered, and most well known, for its role in causing humoral hypercalcemia of malignancy, PTHrP is expressed in normal tissues and plays an important role in lung development and maturation, normal alveolar physiology, surfactant synthesis, recovery from lung injury and inflammation (<xref ref-type="table" rid="table1-1944451612443067">Table 1</xref>). Given its role in these processes, PTHrP-based therapies could hold promise in treating both neonatal and adult lung injury, though this remains speculative at this time. Perhaps more readily translatable to clinical practice is the use of PTHrP as a biomarker. Levels of PTHrP in tracheal aspirates or BAL could provide additional information when assessing lung maturation in neonates or the degree of injury and prognosis in patients with acute lung injury, and may even help predict who will develop lung injury in patients at risk.</p>
<table-wrap id="table1-1944451612443067" position="float">
<label>Table 1.</label>
<caption>
<p>Summary of the Effects of Parathyroid Hormone–Related Protein (PTHrP) in Lung, Lung Disease, and Inflammation</p>
</caption>
<graphic alternate-form-of="table1-1944451612443067" xlink:href="10.1177_1944451612443067-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Context</th>
<th align="center">Roles of PTHrP</th>
<th align="center">References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung development</td>
<td>Bone development (thoracic cage); branching morphogenesis; maturation of type II pneumocyte function; maintain fetal lung fibroblasts as lipofibroblasts and stimulate them to produce surfactant lipid precursors and leptin</td>
<td><xref ref-type="bibr" rid="bibr12-1944451612443067">12</xref><xref ref-type="bibr" rid="bibr13-1944451612443067"/><xref ref-type="bibr" rid="bibr14-1944451612443067"/><xref ref-type="bibr" rid="bibr15-1944451612443067"/>-<xref ref-type="bibr" rid="bibr16-1944451612443067">16</xref></td>
</tr>
<tr>
<td>Adult lung</td>
<td>Stimulate surfactant production; decrease proliferation of type II pneumocytes; sensitize type II cells to apoptosis</td>
<td><xref ref-type="bibr" rid="bibr20-1944451612443067">20</xref><xref ref-type="bibr" rid="bibr21-1944451612443067"/>-<xref ref-type="bibr" rid="bibr22-1944451612443067">22</xref></td>
</tr>
<tr>
<td>Lung injury</td>
<td>Regulate type II pneumocyte proliferation in response to injury; deficiency may contribute to bronchopulmonary dysplasia; levels correlate with severity of lung injury</td>
<td><xref ref-type="bibr" rid="bibr25-1944451612443067">25</xref><xref ref-type="bibr" rid="bibr26-1944451612443067"/><xref ref-type="bibr" rid="bibr27-1944451612443067"/><xref ref-type="bibr" rid="bibr28-1944451612443067"/><xref ref-type="bibr" rid="bibr29-1944451612443067"/><xref ref-type="bibr" rid="bibr30-1944451612443067"/>-<xref ref-type="bibr" rid="bibr31-1944451612443067">31</xref></td>
</tr>
<tr>
<td>Pulmonary hypertension</td>
<td>Smooth muscle relaxation—vasodilation; deficiency may contribute to pulmonary vascular disease</td>
<td><xref ref-type="bibr" rid="bibr10-1944451612443067">10</xref>, <xref ref-type="bibr" rid="bibr11-1944451612443067">11</xref>, <xref ref-type="bibr" rid="bibr23-1944451612443067">23</xref>, <xref ref-type="bibr" rid="bibr24-1944451612443067">24</xref></td>
</tr>
<tr>
<td>Inflammation</td>
<td>Improve outcome after ischemic injury in brain and heart; beneficial or deleterious effects in sepsis depending on severity</td>
<td><xref ref-type="bibr" rid="bibr32-1944451612443067">32</xref>, <xref ref-type="bibr" rid="bibr33-1944451612443067">33</xref></td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="supported-by">
<p>This material is supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, BLR&amp;D Career Development Award (PRM) and BLR&amp;D Merit Review Award (RHH).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1944451612443067">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goltzman</surname><given-names>D</given-names></name>
<name><surname>Hendy</surname><given-names>GN</given-names></name>
<name><surname>Banville</surname><given-names>D</given-names></name>
</person-group>. <article-title>Parathyroid hormone-like peptide: molecular characterization and biological properties</article-title>. <source>Trends Endocrinol Metab</source>. <year>1989</year>;<volume>1</volume>:<fpage>39</fpage>-<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr2-1944451612443067">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Orloff</surname><given-names>JJ</given-names></name>
<name><surname>Reddy</surname><given-names>D</given-names></name>
<name><surname>de Papp</surname><given-names>AE</given-names></name>
<name><surname>Yang</surname><given-names>KH</given-names></name>
<name><surname>Soifer</surname><given-names>NE</given-names></name>
<name><surname>Stewart</surname><given-names>AF</given-names></name>
</person-group>. <article-title>Parathyroid hormone-related protein as a prohormone: posttranslational processing and receptor interactions</article-title>. <source>Endocrine Rev</source>. <year>1994</year>;<volume>15</volume>:<fpage>40</fpage>-<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr3-1944451612443067">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deftos</surname><given-names>LJ</given-names></name>
<name><surname>Burton</surname><given-names>DW</given-names></name>
<name><surname>Hastings</surname><given-names>RH</given-names></name>
<name><surname>Terkeltaub</surname><given-names>R</given-names></name>
<name><surname>Hook</surname><given-names>VY</given-names></name>
</person-group>. <article-title>Comparative tissue distribution of the processing enzymes “prohormone thiol protease,” and prohormone convertases 1 and 2, in human PTHrP-producing cell lines and mammalian neuroendocrine tissues</article-title>. <source>Endocrine</source>. <year>2001</year>;<volume>15</volume>:<fpage>217</fpage>-<lpage>224</lpage>.</citation>
</ref>
<ref id="bibr4-1944451612443067">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Luparello</surname><given-names>C</given-names></name>
<name><surname>Romanotto</surname><given-names>R</given-names></name>
<name><surname>Tipa</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Midregion parathyroid hormone-related protein inhibits growth and invasion in vitro and tumorigenesis in vivo of human breast cancer cells</article-title>. <source>J Bone Mineral Res</source>. <year>2001</year>;<volume>16</volume>:<fpage>2173</fpage>-<lpage>2181</lpage>.</citation>
</ref>
<ref id="bibr5-1944451612443067">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>MH</given-names></name>
<name><surname>McCaughan</surname><given-names>HB</given-names></name>
<name><surname>Papadimitriou</surname><given-names>JM</given-names></name>
<name><surname>Nicholson</surname><given-names>GC</given-names></name>
<name><surname>Wood</surname><given-names>DJ</given-names></name>
</person-group>. <article-title>Tartrate resistant acid phosphatase activity in rat cultured osteoclasts is inhibited by a carboxyl terminal peptide (osteostatin) from parathyroid hormone-related protein</article-title>. <source>J Cell Biochem</source>. <year>1994</year>;<volume>54</volume>:<fpage>145</fpage>-<lpage>153</lpage>.</citation>
</ref>
<ref id="bibr6-1944451612443067">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goomer</surname><given-names>RS</given-names></name>
<name><surname>Johnson</surname><given-names>KA</given-names></name>
<name><surname>Burton</surname><given-names>DW</given-names></name><etal/>
</person-group>. <article-title>The tetrabasic KKKK 147-150 motif determines intracrine regulatory effects of PTHrP 1-173 on chondrocyte PPi metabolism and matrix synthesis</article-title>. <source>Endocrinology</source>. <year>2000</year>;<volume>141</volume>:<fpage>4613</fpage>-<lpage>4622</lpage>.</citation>
</ref>
<ref id="bibr7-1944451612443067">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Henderson</surname><given-names>JE</given-names></name>
<name><surname>Amizuka</surname><given-names>N</given-names></name>
<name><surname>Warshawsky</surname><given-names>H</given-names></name><etal/>
</person-group>. <article-title>Nucleolar localization of parathyroid hormone-related peptide enhances survival of chondrocytes under conditions that promote apoptotic cell death</article-title>. <source>Mol Cell Biol</source>. <year>1995</year>;<volume>15</volume>:<fpage>4064</fpage>-<lpage>4075</lpage>.</citation>
</ref>
<ref id="bibr8-1944451612443067">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pache</surname><given-names>JC</given-names></name>
<name><surname>Burton</surname><given-names>DW</given-names></name>
<name><surname>Deftos</surname><given-names>LJ</given-names></name>
<name><surname>Hastings</surname><given-names>RH</given-names></name>
</person-group>. <article-title>A carboxyl leucine-rich region of parathyroid hormone-related protein is critical for nuclear export</article-title>. <source>Endocrinology</source>. <year>2005</year>;<volume>147</volume>:<fpage>990</fpage>-<lpage>998</lpage>.</citation>
</ref>
<ref id="bibr9-1944451612443067">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Massfelder</surname><given-names>T</given-names></name>
<name><surname>Dann</surname><given-names>P</given-names></name>
<name><surname>Wu</surname><given-names>TL</given-names></name>
<name><surname>Vasavada</surname><given-names>R</given-names></name>
<name><surname>Helwig</surname><given-names>JJ</given-names></name>
<name><surname>Stewart</surname><given-names>AF</given-names></name>
</person-group>. <article-title>Opposing mitogenic and anti-mitogenic actions of parathyroid hormone-related protein in vascular smooth muscle cells: a critical role for nuclear targeting</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1997</year>;<volume>94</volume>:<fpage>13630</fpage>-<lpage>13635</lpage>.</citation>
</ref>
<ref id="bibr10-1944451612443067">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shenberger</surname><given-names>JS</given-names></name>
<name><surname>Shew</surname><given-names>RL</given-names></name>
<name><surname>Johnson</surname><given-names>DE</given-names></name>
<name><surname>Kannan</surname><given-names>MS</given-names></name>
</person-group>. <article-title>Relaxation of porcine tracheal smooth muscle by parathyroid hormone-related protein</article-title>. <source>Respir Physiol</source>. <year>1997</year>;<volume>107</volume>:<fpage>596</fpage>-<lpage>566</lpage>.</citation>
</ref>
<ref id="bibr11-1944451612443067">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gao</surname><given-names>Y</given-names></name>
<name><surname>Raj</surname><given-names>JU</given-names></name>
</person-group>. <article-title>Parathyroid hormone-related protein-mediated responses in pulmonary arteries and veins of newborn lambs</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>. <year>2005</year>;<volume>289</volume>:<fpage>L60</fpage>-<lpage>L66</lpage>.</citation>
</ref>
<ref id="bibr12-1944451612443067">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Karaplis</surname><given-names>AC</given-names></name>
<name><surname>Luz</surname><given-names>A</given-names></name>
<name><surname>Glowacki</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene</article-title>. <source>Genes Devel</source>. <year>1994</year>;<volume>8</volume>:<fpage>277</fpage>-<lpage>289</lpage>.</citation>
</ref>
<ref id="bibr13-1944451612443067">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lanske</surname><given-names>B</given-names></name>
<name><surname>Karaplis</surname><given-names>AC</given-names></name>
<name><surname>Lee</surname><given-names>K</given-names></name><etal/>
</person-group>. <article-title>PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth</article-title>. <source>Science</source>. <year>1996</year>;<volume>273</volume>:<fpage>663</fpage>-<lpage>666</lpage>.</citation>
</ref>
<ref id="bibr14-1944451612443067">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rubin</surname><given-names>LP</given-names></name>
<name><surname>Kovacs</surname><given-names>CA</given-names></name>
<name><surname>Tsai</surname><given-names>S-W</given-names></name>
<name><surname>Pinar</surname><given-names>H</given-names></name>
<name><surname>Torday</surname><given-names>JS</given-names></name>
<name><surname>Kronenberg</surname><given-names>HM</given-names></name>
</person-group>. <article-title>The parathyroid hormone-related protein (PTHrP) knockout mouse shows delayed lung development</article-title>. <source>Pediatric Res</source>. <year>1997</year>;<volume>41</volume>:266a.</citation>
</ref>
<ref id="bibr15-1944451612443067">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rubin</surname><given-names>LP</given-names></name>
<name><surname>Kifor</surname><given-names>O</given-names></name>
<name><surname>Hua</surname><given-names>J</given-names></name>
<name><surname>Brown</surname><given-names>EM</given-names></name>
<name><surname>Torday</surname><given-names>JS</given-names></name>
</person-group>. <article-title>Parathyroid hormone (PTH) and PTH-related protein stimulate surfactant phospholipid synthesis in rat fetal lung, apparently by a mesenchymal-epithelial mechanism</article-title>. <source>Biochim Biophys Acta</source>. <year>1994</year>;<volume>1223</volume>:<fpage>91</fpage>-<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr16-1944451612443067">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Torday</surname><given-names>JS</given-names></name>
<name><surname>Sun</surname><given-names>H</given-names></name>
<name><surname>Wang</surname><given-names>L</given-names></name>
<name><surname>Torres</surname><given-names>E</given-names></name>
<name><surname>Sunday</surname><given-names>ME</given-names></name>
<name><surname>Rubin</surname><given-names>LP</given-names></name>
</person-group>. <article-title>Leptin mediates the parathyroid hormone-related protein paracrine stimulation of fetal lung maturation</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>. <year>2002</year>;<volume>282</volume>:<fpage>L405</fpage>-<lpage>L410</lpage>.</citation>
</ref>
<ref id="bibr17-1944451612443067">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krebs</surname><given-names>M</given-names></name>
<name><surname>Sakurai</surname><given-names>R</given-names></name>
<name><surname>Torday</surname><given-names>JS</given-names></name>
<name><surname>Rehan</surname><given-names>VK</given-names></name>
</person-group>. <article-title>Evidence for in vivo nicotine-induced alveolar interstitial fibroblast-to-myofibroblast transdifferentiation</article-title>. <source>Exp Lung Res</source>. <year>2010</year>;<volume>36</volume>:<fpage>390</fpage>-<lpage>398</lpage>.</citation>
</ref>
<ref id="bibr18-1944451612443067">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rehan</surname><given-names>VK</given-names></name>
<name><surname>Sakurai</surname><given-names>R</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Santos</surname><given-names>J</given-names></name>
<name><surname>Huynh</surname><given-names>K</given-names></name>
<name><surname>Torday</surname><given-names>JS</given-names></name>
</person-group>. <article-title>Reversal of nicotine-induced alveolar lipofibroblast-to-myofibroblast transdifferentiation by stimulants of parathyroid hormone-related protein signaling</article-title>. <source>Lung</source>. <year>2007</year>;<volume>185</volume>:<fpage>151</fpage>-<lpage>159</lpage>.</citation>
</ref>
<ref id="bibr19-1944451612443067">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rehan</surname><given-names>VK</given-names></name>
<name><surname>Asotra</surname><given-names>K</given-names></name>
<name><surname>Torday</surname><given-names>JS</given-names></name>
</person-group>. <article-title>The effects of smoking on the developing lung: insights from a biologic model for lung development, homeostasis, and repair</article-title>. <source>Lung</source>. <year>2009</year>;<volume>187</volume>:<fpage>281</fpage>-<lpage>289</lpage>.</citation>
</ref>
<ref id="bibr20-1944451612443067">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hastings</surname><given-names>RH</given-names></name>
<name><surname>Summers-Torres</surname><given-names>D</given-names></name>
<name><surname>Cheung</surname><given-names>TC</given-names></name><etal/>
</person-group>. <article-title>Parathyroid hormone-related protein, an autocrine regulatory factor for alveolar epithelial cells</article-title>. <source>Am J Physiol</source>. <year>1996</year>;<volume>270</volume>:<fpage>L353</fpage>-<lpage>L361</lpage>.</citation>
</ref>
<ref id="bibr21-1944451612443067">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hastings</surname><given-names>RH</given-names></name>
<name><surname>Summers-Torres</surname><given-names>D</given-names></name>
<name><surname>Yaszay</surname><given-names>B</given-names></name>
<name><surname>LeSueur</surname><given-names>J</given-names></name>
<name><surname>Burton</surname><given-names>DW</given-names></name>
<name><surname>Deftos</surname><given-names>LJ</given-names></name>
</person-group>. <article-title>Parathyroid hormone-related protein, an autocrine growth inhibitor of alveolar type II cells</article-title>. <source>Am J Physiol</source>. <year>1997</year>;<volume>272</volume>:<fpage>L394</fpage>-<lpage>L399</lpage>.</citation>
</ref>
<ref id="bibr22-1944451612443067">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hastings</surname><given-names>RH</given-names></name>
<name><surname>Araiza</surname><given-names>F</given-names></name>
<name><surname>Burton</surname><given-names>DW</given-names></name>
<name><surname>Zhang</surname><given-names>L</given-names></name>
<name><surname>Bedley</surname><given-names>M</given-names></name>
<name><surname>Deftos</surname><given-names>LJ</given-names></name>
</person-group>. <article-title>Parathyroid hormone-related protein ameliorates death receptor-mediated apoptosis in lung cancer cells</article-title>. <source>Am J Physiol Cell Physiol</source>. <year>2003</year>;<volume>285</volume>:<fpage>C1429</fpage>-<lpage>C1436</lpage>.</citation>
</ref>
<ref id="bibr23-1944451612443067">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Massfelder</surname><given-names>T</given-names></name>
<name><surname>Fiaschi-Taesch</surname><given-names>N</given-names></name>
<name><surname>Stewart</surname><given-names>AF</given-names></name>
<name><surname>Helwig</surname><given-names>JJ</given-names></name>
</person-group> <article-title>Parathyroid hormone-related peptide: a smooth muscle tone and proliferation regulatory protein</article-title>. <source>Curr Opin Nephrol Hypertens</source>. <year>1998</year>;<volume>7</volume>:<fpage>27</fpage>-<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr24-1944451612443067">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>B</given-names></name>
<name><surname>Morimoto</surname><given-names>S</given-names></name>
<name><surname>Fukuo</surname><given-names>K</given-names></name><etal/>
</person-group>. <article-title>Parathyroid hormone-related protein inhibits endothelin-1 production</article-title>. <source>Hypertension</source>. <year>1996</year>;<volume>27</volume>(<issue>3 pt 1</issue>):<fpage>360</fpage>-<lpage>363</lpage>.</citation>
</ref>
<ref id="bibr25-1944451612443067">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hastings</surname><given-names>RH</given-names></name>
<name><surname>Berg</surname><given-names>JT</given-names></name>
<name><surname>Summers-Torres</surname><given-names>D</given-names></name>
<name><surname>Burton</surname><given-names>DW</given-names></name>
<name><surname>Deftos</surname><given-names>LJ</given-names></name>
</person-group>. <article-title>Parathyroid hormone-related protein reduces alveolar epithelial cell proliferation during lung injury in rats</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>. <year>2000</year>;<volume>279</volume>:<fpage>L194</fpage>-<lpage>L200</lpage>.</citation>
</ref>
<ref id="bibr26-1944451612443067">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hastings</surname><given-names>RH</given-names></name>
<name><surname>Asirvatham</surname><given-names>A</given-names></name>
<name><surname>Quintana</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Parathyroid hormone-related protein-(38-64) regulates lung cell proliferation after silica injury</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>. <year>2002</year>;<volume>283</volume>:<fpage>L12</fpage>-<lpage>L21</lpage>.</citation>
</ref>
<ref id="bibr27-1944451612443067">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stern</surname><given-names>JB</given-names></name>
<name><surname>Bernard</surname><given-names>O</given-names></name>
<name><surname>Paugam</surname><given-names>C</given-names></name><etal/>
</person-group>. <article-title>Parathyroid hormone-related protein in epithelial lining fluid in humans negatively correlates with the severity of lung injury</article-title>. <source>Chest</source>. <year>2002</year>;<volume>121</volume>:<fpage>852</fpage>-<lpage>857</lpage>.</citation>
</ref>
<ref id="bibr28-1944451612443067">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hastings</surname><given-names>RH</given-names></name>
<name><surname>Auger</surname><given-names>WR</given-names></name>
<name><surname>Kerr</surname><given-names>KM</given-names></name>
<name><surname>Quintana</surname><given-names>RA</given-names></name>
<name><surname>Deftos</surname><given-names>LJ</given-names></name>
</person-group>. <article-title>Parathyroid hormone-related protein and lung injury after pulmonary thromboendarterectomy</article-title>. <source>Regul Pept</source>. <year>2001</year>;<volume>102</volume>:<fpage>1</fpage>-<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr29-1944451612443067">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Speziale</surname><given-names>MV</given-names></name>
<name><surname>Mannino</surname><given-names>FL</given-names></name>
<name><surname>Hastings</surname><given-names>RH</given-names></name>
<name><surname>Deftos</surname><given-names>LJ</given-names></name>
</person-group>. <article-title>Parathyroid hormone-related protein in tracheal aspirates of newborn infants</article-title>. <source>Pediatr Res</source>. <year>1998</year>;<volume>43</volume>:<fpage>660</fpage>-<lpage>665</lpage>.</citation>
</ref>
<ref id="bibr30-1944451612443067">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rehan</surname><given-names>VK</given-names></name>
<name><surname>Torday</surname><given-names>JS</given-names></name>
</person-group>. <article-title>Lower parathyroid hormone-related protein content of tracheal aspirates in very low birth weight infants who develop bronchopulmonary dysplasia</article-title>. <source>Pediatr Res</source>. <year>2006</year>;<volume>60</volume>:<fpage>216</fpage>-<lpage>220</lpage>.</citation>
</ref>
<ref id="bibr31-1944451612443067">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rehan</surname><given-names>VK</given-names></name>
<name><surname>Torday</surname><given-names>JS</given-names></name>
</person-group>. <article-title>Exploiting the PTHrP signaling pathway to treat chronic lung disease</article-title>. <source>Drugs Today (Barc)</source>. <year>2007</year>;<volume>43</volume>:<fpage>317</fpage>-<lpage>331</lpage>.</citation>
</ref>
<ref id="bibr32-1944451612443067">
<label>32.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Funk</surname><given-names>JL</given-names></name>
</person-group>. <article-title>PTHrP and inflammation</article-title>. In: <person-group person-group-type="editor">
<name><surname>Luparello</surname><given-names>C</given-names></name>
</person-group>, ed. <source>Novel Aspects of PTHrP Physiopathology</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Nova Biomedical Books</publisher-name>; <volume>2007</volume>:<fpage>165</fpage>-<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr33-1944451612443067">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Funk</surname><given-names>JL</given-names></name>
</person-group>. <article-title>A role for parathyroid hormone-related protein in the pathogenesis of inflammatory/autoimmune diseases</article-title>. <source>Int Immunopharmacol</source>. <year>2001</year>;<volume>1</volume>:<fpage>1101</fpage>-<lpage>1121</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>